| Year |
Citation |
Score |
| 2005 |
Gooden KM, Carter-Edwards L, Hoyo C, Akbar J, Cleveland RJ, Oates V, Jackson E, Furberg H, Gammon MD. Perceptions of participation in an observational epidemiologic study of cancer among African Americans. Ethnicity & Disease. 15: 68-75. PMID 15720051 |
0.301 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2014 |
Saglio G, le Coutre P, Cortes JE, Mayer J, Rowlings PA, Mahon F, Kroog GS, Gooden K, Subar M, Preston JA, Shah NP. The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program Blood. 124: 4534-4534. DOI: 10.1182/Blood.V124.21.4534.4534 |
0.142 |
|
| 2007 |
Boyington JE, Howard DL, Carter-Edwards L, Gooden KM, Erdem N, Jallah Y, Busby-Whitehead J. Differences in resident characteristics and prevalence of urinary incontinence in nursing homes in the southeastern United States. Nursing Research. 56: 97-107. PMID 17356440 DOI: 10.1097/01.NNR.0000263969.08878.51 |
0.139 |
|
| 2017 |
Rao S, Gooden KM, Landsman-Blumberg P, Yue B, Lankford ML, Dreicer R. Treatment patterns and economic burden of illness in patients with advanced bladder cancer receiving second-line therapy. Journal of Clinical Oncology. 35: 320-320. DOI: 10.1200/JCO.2017.35.6_suppl.320 |
0.137 |
|
| 2017 |
Necchi A, Grimm M, Retz M, Arranz Arija JA, Bracarda S, Bedke J, Baron AD, Sharma P, Galsky MD, Vaena DA, Kalinka-Warzocha E, Cwikiel M, Pal SK, Morales R, Taylor F, ... Gooden KM, et al. Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275. Journal of Clinical Oncology. 35: 4526-4526. DOI: 10.1200/jco.2017.35.15_suppl.4526 |
0.134 |
|
| 2022 |
Signorovitch J, Moshyk A, Zhao J, Le TK, Burns L, Gooden K, Hamilton M. Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma. Future Oncology (London, England). PMID 35048743 DOI: 10.2217/fon-2021-1054 |
0.128 |
|
| 2020 |
Hemstock M, Amadi A, Kupas K, Roskell N, Kotapati S, Gooden K, Middleton MR, Schadendorf D. Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma. European Journal of Cancer (Oxford, England : 1990). 132: 176-186. PMID 32380428 DOI: 10.1016/j.ejca.2020.03.011 |
0.115 |
|
| 2018 |
Pond GR, Sonpavde G, Galsky MD, Sharma P, Rosenberg JE, Choueiri TK, Bellmunt J, Lee J, Lee SI, Azrilevich A, Yang S, Gooden KM, Bajorin DF. Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma. Journal of Clinical Oncology. 36: 451-451. DOI: 10.1200/JCO.2018.36.6_SUPPL.451 |
0.114 |
|
| 2017 |
Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Annals of Hematology. PMID 28534184 DOI: 10.1007/S00277-017-3012-Z |
0.11 |
|
| 2019 |
Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, ... ... Gooden K, et al. Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. International Journal of Clinical Oncology. PMID 31218529 DOI: 10.1007/s10147-019-01450-w |
0.106 |
|
| 2007 |
Gooden KM, Schroeder JC, North KE, Gammon MD, Hartmann KE, Taylor J, Baird DD. Val153Met polymorphism of catechol-O-methyltransferase and prevalence of uterine leiomyomata. Reproductive Sciences (Thousand Oaks, Calif.). 14: 117-20. PMID 17636223 DOI: 10.1177/1933719106298687 |
0.096 |
|
| 2005 |
Gooden KM, Carter-Edwards L, Hoyo C, Akbar J, Cleveland RJ, Oates V, Jackson E, Furberg H, Gammon MD. For the patient. Recruitment strategies for cancer research studies. Ethnicity & Disease. 15: 151. PMID 15720063 |
0.089 |
|
| 2022 |
Broughton EI, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G. Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Bmc Urology. 22: 27. PMID 35219307 DOI: 10.1186/s12894-022-00959-z |
0.087 |
|
| 2019 |
Lakhdari K, Young K, Berling M, Gooden K, Holdgate O. PCN240 EVALUATING PARTITIONED SURVIVAL MODEL AND RESPONSE-BASED MODELING APPROACHES FOR USE IN COST-EFFECTIVENESS ANALYSIS: ESTIMATING AND VALIDATING SURVIVAL OUTCOMES Value in Health. 22: S101-S102. DOI: 10.1016/J.JVAL.2019.04.361 |
0.085 |
|
| 2022 |
Chun DS, Hicks B, Peacock Hinton S, Jonsson-Funk M, Gooden K, Keil AP, Tan HJ, Stürmer T, Lund JL. Comparison of approaches for measuring adherence and persistence to oral oncologic therapies in patients diagnosed with metastatic renal cell carcinoma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 35064061 DOI: 10.1158/1055-9965.EPI-21-0341 |
0.085 |
|
| 2022 |
Broughton EI, Chun DS, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G. Treatment and disease management patterns for bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis. Current Urology. 16: 147-153. PMID 36204362 DOI: 10.1097/CU9.0000000000000072 |
0.083 |
|
| 2008 |
Gooden KM, Howard DL, Carpenter WR, Carson AP, Taylor YJ, Peacock S, Godley PA. The effect of hospital and surgeon volume on racial differences in recurrence-free survival after radical prostatectomy. Medical Care. 46: 1170-6. PMID 18953228 DOI: 10.1097/Mlr.0B013E31817D696D |
0.079 |
|
| 2019 |
Kurt M, May J, Malcolm B, Gooden K, Borrill J, Holdgate O, Teitsson S. PCN146 VALIDATION OF PREDICTED SURVIVAL ESTIMATES FROM PREVIOUS DATA CUTS OF THE PHASE III CHECKMATE 025 STUDY IN ADVANCED RENAL CELL CARCINOMA Value in Health. 22: S463-S464. DOI: 10.1016/j.jval.2019.09.342 |
0.079 |
|
| 2019 |
Cakar E, May J, Malcolm B, Gooden K, Klijn S. PCN23 UPDATED NETWORK META-ANALYSIS OF TREATMENTS IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA Value in Health. 22: S439. DOI: 10.1016/j.jval.2019.09.220 |
0.077 |
|
| 2019 |
Cakar E, May J, Malcolm B, Gooden K, Klijn S. PCN421 STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA Value in Health. 22: S517-S518. DOI: 10.1016/j.jval.2019.09.614 |
0.077 |
|
| 2019 |
Oniangue-Ndza C, Schneider R, Malcolm B, May J, Gooden K, Klijn S, Cakar E. PCN140 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO SUNITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SWITZERLAND Value in Health. 22: S462. DOI: 10.1016/j.jval.2019.09.336 |
0.076 |
|
| 2019 |
Polanco Sánchez C, Pérez-Alcántara F, May J, Gooden K, Malcolm B, Arranz J, Duran I, García-Donas J, Gallardo E, Láinez N, Maroto P, Valderrama B, Puente J, Vázquez S, Van de Wetering G, et al. PCN157 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN Value in Health. 22: S466. DOI: 10.1016/j.jval.2019.09.353 |
0.075 |
|
| 2019 |
Oniangue-Ndza C, Gooden K, May J, Malcolm B, Du E, Yin L, Betts K. PCN111 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SWITZERLAND Value in Health. 22: S457. DOI: 10.1016/j.jval.2019.09.308 |
0.073 |
|
| 2023 |
W DeClue R, Fisher MD, Gooden K, Walker MS, Le TK. Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy. Future Oncology (London, England). PMID 37191097 DOI: 10.2217/fon-2022-0894 |
0.064 |
|
| 2019 |
Tanova N, Yang S, Cheung L, Genestier V, Gooden K, Malcolm B, Rao S, Choueiri T. PCN127 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED WITH CURRENTLY AVAILABLE FIRST-LINE TREATMENTS IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC RENAL CELL CARCINOMA IN THE UNITED STATES Value in Health. 22: S80. DOI: 10.1016/J.JVAL.2019.04.251 |
0.059 |
|
| 2019 |
Batteson R, Hart R, Hemstock M, Gooden K, Kotapati S, Roze S, Lee D, Amadi A. Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection. Pharmacoeconomics - Open. PMID 31587138 DOI: 10.1007/s41669-019-00181-y |
0.058 |
|
| 2019 |
Shah R, Botteman M, Kwon Y, Gooden K, Cella D, Motzer R. PCN264 QUALITY ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE PROGRESSION OR TOXICITY (Q-TWIST) OF NIVOLUMAB PLUS IPILIMUMAB (NIVO+IPI) VS SUNITINIB (SUN) AMONG UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS (PATIENTS) WITH INTERMEDIATE OR POOR PROGNOSTIC RISK Value in Health. 22: S106. DOI: 10.1016/J.JVAL.2019.04.385 |
0.052 |
|
| 2013 |
Gooden KM, Pan X, Kawabata H, Heim JM. Use of an algorithm for identifying hidden drug–drug interactions in adverse event reports. Journal of the American Medical Informatics Association : Jamia. 20: 590. PMID 23268484 DOI: 10.1136/amiajnl-2012-001234 |
0.047 |
|
| 2019 |
Polanco Sánchez C, Alves D, Gooden K, May J, Malcolm B, Du E, Betts K. PCN26 QUANTIFYING THE RELATIVE CLINICAL VALUE OF NIVOLUMAB PLUS IPILIMUMAB VS. SUNITINIB IN FIRST-LINE ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH THE NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM IN SPAIN AND PORTUGAL Value in Health. 22: S440. DOI: 10.1016/j.jval.2019.09.223 |
0.046 |
|
| 2019 |
Cella D, Escudier B, Ivanescu C, Mauer M, Lord-Bessen J, Gooden K. Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: Updated results Annals of Oncology. 30: v383-v384. DOI: 10.1093/annonc/mdz249.047 |
0.039 |
|
| 2015 |
Gooden KM, Bibeau KB, Wood J, Irizarry MC, Pan X, Allen J, Sampson T, Heim JM. Incidence of type 2 diabetes among patients exposed to the combination of pravastatin and paroxetine. Current Drug Safety. 10: 152-8. PMID 24861991 |
0.022 |
|
| 2019 |
Regan M, Atkins M, Powles T, Werner L, Mantia C, Yang S, Johansen J, Rao S, Gooden K, McDermott D. Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma Annals of Oncology. 30: v393-v394. DOI: 10.1093/annonc/mdz249.067 |
0.019 |
|
| Hide low-probability matches. |